Overview

Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

Status:
Completed

Trial end date:
2019-06-06

Target enrollment:

Participant gender:

Summary

There are insufficient data on the safety and efficacy of edoxaban plus antiplatelet therapy in subjects with atrial fibrillation (AF) following percutaneous intervention (PCI) with stenting. This study is designed to evaluate the safety and to explore the efficacy of an edoxaban-based antithrombotic regimen versus a vitamin K antagonist (VKA)-based antithrombotic regimen in subjects with AF following PCI with stent placement. Bleeding is a central safety outcome in cardiovascular clinical trials, especially for antithrombotic strategies and invasive procedures.

Phase:

Phase 3

Details

Lead Sponsor:

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Daiichi Sankyo Inc.

Collaborators:

Chiltern International Inc.
European Cardiovascular Research Institute
Kompetenznetz Vorhofflimmern e.V.

Treatments:

Clopidogrel
Edoxaban
Prasugrel Hydrochloride
Ticagrelor
Vitamin K
Vitamins